Navigation Links
Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial

- TARGIT Procedure May Eliminate 6 Weeks of Radiation Therapy - Event: Watch Single-Dose Radiation Treatment over the Internet Wednesday, October 22, 2008, 3 - 4 p.m. by visiting

HAMPTON, Va., Oct. 6 /PRNewswire/ - Questions raced through Vela Cross' mind when she was diagnosed with breast cancer in May. Would she have the tumor removed or her entire breast? How about radiation or chemotherapy?

To view the Multimedia News Release, go to:

With doctors at Sentara CarePlex Hospital involved in the international TARGIT Trial, Cross became the first East Coast patient to receive this revolutionary treatment option.

Sentara CarePlex Hospital in Hampton, Virginia is among five U.S. centers and 22 worldwide enrolling patients in this study open to early-stage breast cancer patients. The study evaluates the effectiveness of an investigational single-dose internal radiation treatment compared with conventional external radiation.

The TARGIT Trial, which stands for TARGeted Intraoperative-radiation Therapy, could eliminate the need for six weeks of daily radiation.

"Regular radiation would have really interrupted my life," says Cross.

"Some women consider a mastectomy rather than facing weeks of conventional radiation," says surgical oncologist Dr. Richard Hoefer. "We hope our participation offers women another option," he continues.

Half of trial participants get the investigational one-time dose of radiation through an applicator placed in the tumor cavity. The radiation is targeted to breast cells with the highest risk of cancer recurrence-those that directly surrounded the tumor. Other trial participants receive 6-8 weeks of external radiation.

Equipment involved in this study was cleared by the U.S. FDA as safe and effective; trials at Sentara are subject to rigorous approvals.

"This study could significantly change the way we care for early-stage breast cancer patients," says Dr. Michael Miller, medical director of CarePlex Hospital's radiation oncology department.

TARGIT is a randomized phase III study, enrolling post-menopausal women at least 45 years old with single-site invasive breast cancer measuring less than 3 centimeters. For a patient to receive the single-dose radiation, they must be a candidate for the TARGIT Trial. Other considerations include type of cancer, tumor size, and lymph node involvement. To learn more, call 757-594- 1939 or visit

SOURCE Sentara CarePlex Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
(Date:12/1/2015)...  The migration to value-based care will require ... that help patients stay healthy and reduce healthcare ... enabled, incorporate care guidelines and be reflective of ... also allow all stakeholders to collaborate across care ... That is the vision, however, research by Chilmark ...
(Date:12/1/2015)... -- --> --> ... (NKI-AVL), among the world,s largest and most prestigious ... Icon™, the company,s latest generation stereotactic radiosurgery system ... --> With the option to use ... Knife Icon offers greatly enhanced flexibility in how ...
(Date:12/1/2015)... , December 1, 2015 ... segments the concerned market with analysis and forecast of ... orthobiologics report defines and segments the concerned market with ... to the Market Research Report "North American Orthobiologics Market ... Factors & Spinal Stimulation, Stem Cell Therapy, Viscosupplementation), by ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest ... Integration ,” addresses a main “pain point” for merging or aligning healthcare provider ... a deal is signed. This quick-read guidance suggests that failing to recognize ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., ... largest order to date. , The order will be from the China Disabled ... Cochlear Implant System is an effective solution for children and adults suffering from ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... companies, announced today that it has officially launched a sleek, mobile-ready and user-centric ... that his company’s new website clearly outlines the benefits that its SEO services ...
(Date:11/30/2015)... , ... December 01, 2015 , ... ... Christina Colon as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:11/30/2015)... MN (PRWEB) , ... December 01, 2015 , ... ... is the latest carrier to offer individual vision insurance plans on ... the unique ability to rate and review products, allowing consumers to compare, quote ...
Breaking Medicine News(10 mins):